Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 18 years or older with documented MDS (including MDS-subtype, CMML) or AML (as defined by WHO criteria)~2. Severe thrombocytopenia defined as a platelet count of ≤ 10 x 109/L documented on two consecutive samples at least 7 days apart.~3. Receiving outpatient-based supportive or palliative care including palliative cytoreductive, immunomodulatory or hypomethylating therapy, e.g. hydroxyurea or low dose cytarabine, lenalidomide, azacytidine, or decitabine.~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.~Exclusion Criteria:~1. High-dose therapy in past 2 months, e.g. AML-type induction or consolidation therapy~2. Thrombocytopenia suspected to be due to immune or peripheral destruction~3. Splenomegaly, palpated at greater than 5 cm below the costal margin or greater than 20 cm on imaging~4. Alloimmune platelet refractoriness~5. Clinically relevant bleed (grade 3 or higher) within the past 3 months~6. Coagulopathy (prothrombin time or activated partial thromboplastin more than 1.5 times the upper limit of normal or fibrinogen less than 2 g/L)~7. Require anticoagulant therapy, e.g. heparin, or antiplatelet therapy, e.g. aspirin~8. Significant renal impairment (Creatinine more than 1.5 times the upper limit of normal)~9. Geographic inaccessibility resulting in the inability to comply with follow-up visits~10. Pregnant or breast-feeding~11. Unwilling or unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Platelet Transfusion Arm (Type: EXPERIMENTAL): Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
- Prophylactic Platelet Transfusion Group (Type: ACTIVE_COMPARATOR): Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is \< 10 x 109/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).